Patents Assigned to Neotope Biosciences Limited
-
Publication number: 20150056187Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: ApplicationFiled: July 24, 2014Publication date: February 26, 2015Applicant: NEOTOPE BIOSCIENCES LIMITEDInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20150024433Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: ApplicationFiled: July 24, 2014Publication date: January 22, 2015Applicant: NEOTOPE BIOSCIENCES LIMITEDInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Publication number: 20140348843Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.Type: ApplicationFiled: May 28, 2014Publication date: November 27, 2014Applicant: NEOTOPE BIOSCIENCES LIMITEDInventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
-
Publication number: 20140314744Abstract: Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin ?4 chain, e.g., an ?4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS.Type: ApplicationFiled: June 6, 2012Publication date: October 23, 2014Applicant: Neotope Biosciences LimitedInventors: Kenneth Flanagan, Jennifer Johnston, Theodore Yednock, Jeanne Baker
-
Publication number: 20140275495Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.Type: ApplicationFiled: January 15, 2014Publication date: September 18, 2014Applicant: Neotope Biosciences LimitedInventors: José William Saldanha, Tarlochan S. Nijjar
-
Patent number: 8790644Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.Type: GrantFiled: January 25, 2013Date of Patent: July 29, 2014Assignee: Neotope Biosciences LimitedInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Patent number: 8741298Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.Type: GrantFiled: February 7, 2012Date of Patent: June 3, 2014Assignee: Neotope Biosciences LimitedInventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
-
Publication number: 20140127225Abstract: The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment.Type: ApplicationFiled: October 7, 2013Publication date: May 8, 2014Applicant: Neotope Biosciences LimitedInventors: Guriqbal S. Basi, Robin Barbour, Yue Liu
-
Patent number: 8697082Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: August 9, 2004Date of Patent: April 15, 2014Assignees: Neotope Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah
-
Patent number: 8609820Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.Type: GrantFiled: October 26, 2012Date of Patent: December 17, 2013Assignee: Neotope Biosciences LimitedInventors: Jose Saldanha, Tarlochan S. Nijjar
-
Patent number: 8506959Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: July 19, 2005Date of Patent: August 13, 2013Assignees: Neotope Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20130108546Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: Neotope Biosciences LimitedInventor: Neotope Biosciences Limited
-
Publication number: 20120204275Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.Type: ApplicationFiled: February 7, 2012Publication date: August 9, 2012Applicant: Neotope Biosciences LimitedInventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
-
Patent number: 8147833Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 22, 2008Date of Patent: April 3, 2012Assignees: Neotope Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Patent number: 8092801Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: February 25, 2008Date of Patent: January 10, 2012Assignee: Neotope Biosciences LimitedInventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
